Cirrhosis/Liver Failure News

Statin use significantly decreased decompensation in patients with HBV- and HCV-related cirrhosis, with a borderline effect observed in patients with alcoholic cirrhosis, according to recently published study results.

The Acute Liver Failure Study Group recruited its 3,000th participant in its ongoing multicenter study on acute liver failure, funded by the NIH, according to a press release from the UT Southwestern Medical Center.

Statins were cost-effective and generally well-tolerated, and their benefits often outweighed their potential hepatotoxic risk in patients with severe chronic liver injury and a high risk for developing cardiovascular diseases, according to a recent review of statin studies.

A high BMI in young adult men was associated with an increased risk for developing severe liver disease and hepatocellular carcinoma, particularly in patients who later developed type 2 diabetes, according to recently published study results.

Researchers found that a simplified version of the animal naming verbal response test was an easy, patient-accessible measure for the assessment of hepatic encephalopathy, according to a recently published study.

Directed testing for patients exhibiting signs of common liver diseases saves time, money and results in fewer false positives compared with non-directed testing, according to study results published in Journal of Hepatology.

The AGA has released new guideline recommendations for the diagnosis and management of acute liver failure that advise what tests should or should not be performed and which treatment systems should be implemented.

Long-term carvedilol therapy in patients with liver cirrhosis and ascites was associated with reduced risk of mortality, according to a single-center retrospective analysis.

Advances in pediatric critical care have led to significantly improved outcomes of orthotopic liver transplantation, or OLT, for children with liver failure, according to a retrospective study published in Journal of the American College of Surgeons.

Gold standard monitoring for hepatocellular carcinoma in patients with cirrhosis, as recommended by guidelines, was more cost-effective and beneficial to patients compared with real-life monitoring, according to the results of a simulation study.